奈玛特韦-利托那韦对奥密克戎SARS-CoV-2变异株BA.4和BA.5的真实世界有效性。 - Suppr | 超能文献

Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants.

作者信息

Wong Carlos K H, Lau Kristy T K, Leung Gabriel M

机构信息

Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China.

Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

出版信息

Lancet Infect Dis. 2023 Jun;23(6):639-640. doi: 10.1016/S1473-3099(23)00056-7. Epub 2023 Feb 10.

DOI:10.1016/S1473-3099(23)00056-7

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9917404/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ded/9917404/5e3921ede998/fx1_lrg.jpg

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants.奈玛特韦-利托那韦对奥密克戎SARS-CoV-2变异株BA.4和BA.5的真实世界有效性。

Lancet Infect Dis. 2023 Jun;23(6):639-640. doi: 10.1016/S1473-3099(23)00056-7. Epub 2023 Feb 10.

2

Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.美国科罗拉多州奥密克戎变异株（包括 BA.4 和 BA.5）流行期间门诊 COVID-19 患者使用奈玛特韦-利托那韦的真实世界数据：一项回顾性队列研究。

Lancet Infect Dis. 2023 Jun;23(6):696-705. doi: 10.1016/S1473-3099(23)00011-7. Epub 2023 Feb 10.

3

Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.奥密克戎 BA.2、BA.4/5 和 XBB 传播期间，尼马曲韦/利托那韦在社区居住的新加坡老年人群体中对 COVID-19 住院和重症 COVID-19 的真实世界疗效。

Clin Microbiol Infect. 2023 Oct;29(10):1328-1333. doi: 10.1016/j.cmi.2023.06.016. Epub 2023 Jun 17.

4

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.贝特洛维单抗与奈玛特韦/利托那韦在严重急性呼吸综合征冠状病毒 2 型 BA.2 奥密克戎纪元下高危新冠肺炎患者中的治疗效果相当。

J Infect Dis. 2022 Nov 11;226(10):1683-1687. doi: 10.1093/infdis/jiac346.

5

Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment.新型冠状病毒病复发患者经奈玛特韦/利托那韦治疗后的病毒学和免疫学特征。

Clin Infect Dis. 2023 Feb 8;76(3):e530-e532. doi: 10.1093/cid/ciac496.

6

Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2 in the elderly: A single-center large observational study.奈玛特韦/利托那韦组合治疗老年人感染奥密克戎 BA.2.2 引起的 COVID-19：一项单中心大样本观察性研究。

Immun Inflamm Dis. 2024 Apr;12(4):e1232. doi: 10.1002/iid3.1232.

7

Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding.口服奈玛特韦/利托那韦对 SARS-CoV-2 奥密克戎变异株的短期疗效及培养阳性病毒脱落情况

J Korean Med Sci. 2023 Feb 27;38(8):e59. doi: 10.3346/jkms.2023.38.e59.

8

Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.治疗用单克隆抗体和直接抗病毒药物后，SARS-CoV-2 BA.1 和 BA.2 奥密克戎亚谱系感染的病毒载量下降。

J Med Virol. 2023 Jan;95(1):e28186. doi: 10.1002/jmv.28186. Epub 2022 Oct 7.

9

The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.奈玛特韦/利托那韦在 COVID-19 大流行真实世界数据中的抗病毒效果。

Viruses. 2023 Apr 16;15(4):976. doi: 10.3390/v15040976.

10

Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.新型冠状病毒病 2019 经奈玛特韦/利托那韦治疗后出现症状反弹的临床、病毒学和免疫学评估。

Clin Infect Dis. 2023 Feb 18;76(4):573-581. doi: 10.1093/cid/ciac663.

引用本文的文献

1

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.马来西亚尼马曲韦/利托那韦治疗与 COVID-19 后 180 天发病风险。

BMC Infect Dis. 2024 Aug 5;24(1):780. doi: 10.1186/s12879-024-09679-1.

2

Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.在美国三个医疗系统中，在BQ.1、BQ.1.1和XBB.1.5为主的奥密克戎变种流行期间，新冠门诊患者中奈玛特韦-利托那韦的真实世界使用情况：一项回顾性队列研究

Lancet Reg Health Am. 2024 Feb 9;31:100693. doi: 10.1016/j.lana.2024.100693. eCollection 2024 Mar.

3

Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies.尼马瑞韦/利托那韦治疗轻中度 COVID-19 且有住院高风险患者的有效性：观察性研究的系统评价和荟萃分析。

PLoS One. 2023 Oct 12;18(10):e0284006. doi: 10.1371/journal.pone.0284006. eCollection 2023.